User login
Article Type
Changed
Wed, 05/26/2021 - 13:58
Display Headline
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
Ramucirumab was approved by the US Food and Drug Administration for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after treatment with fluoropyrimidine- or platinum-containing chemotherapy.1,2 Ramucirumab is a recombinant human IgG1 monoclonal antibody directed at vascular endothelial growth factor receptor 2 (VEGFR2). By binding VEGFR2, ramucirumab blocks binding of the VEGFR ligands VEGF-A, VEGF-C, and VEGF-D and thus inhibits ligand-stimulated activation of VEGFR2, including ligand-induced proliferation and migration of endothelial cells. Ramucirumab was shown to inhibit angiogenesis in vivo in animal models. The approval was based on the finding of improved overall survival (OS) in the international double-blind phase 3 REGARD trial (study I4T-IE-JVBD).2,3 Ramucirumab is the first biological treatment given as a single drug that has produced survival benefit in advanced gastric or GEJ adenocarcinoma progressing after first-line treatment, and the study findings validate VEGFR2 signaling as an important target in advanced gastric cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 12(12)
Page Number
428-430
Legacy Keywords
gastric cancer, ramucirumab, anti-VEGF, bevacizumab, aflibercept
Sections
Article PDF
Article PDF
Ramucirumab was approved by the US Food and Drug Administration for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after treatment with fluoropyrimidine- or platinum-containing chemotherapy.1,2 Ramucirumab is a recombinant human IgG1 monoclonal antibody directed at vascular endothelial growth factor receptor 2 (VEGFR2). By binding VEGFR2, ramucirumab blocks binding of the VEGFR ligands VEGF-A, VEGF-C, and VEGF-D and thus inhibits ligand-stimulated activation of VEGFR2, including ligand-induced proliferation and migration of endothelial cells. Ramucirumab was shown to inhibit angiogenesis in vivo in animal models. The approval was based on the finding of improved overall survival (OS) in the international double-blind phase 3 REGARD trial (study I4T-IE-JVBD).2,3 Ramucirumab is the first biological treatment given as a single drug that has produced survival benefit in advanced gastric or GEJ adenocarcinoma progressing after first-line treatment, and the study findings validate VEGFR2 signaling as an important target in advanced gastric cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Ramucirumab was approved by the US Food and Drug Administration for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after treatment with fluoropyrimidine- or platinum-containing chemotherapy.1,2 Ramucirumab is a recombinant human IgG1 monoclonal antibody directed at vascular endothelial growth factor receptor 2 (VEGFR2). By binding VEGFR2, ramucirumab blocks binding of the VEGFR ligands VEGF-A, VEGF-C, and VEGF-D and thus inhibits ligand-stimulated activation of VEGFR2, including ligand-induced proliferation and migration of endothelial cells. Ramucirumab was shown to inhibit angiogenesis in vivo in animal models. The approval was based on the finding of improved overall survival (OS) in the international double-blind phase 3 REGARD trial (study I4T-IE-JVBD).2,3 Ramucirumab is the first biological treatment given as a single drug that has produced survival benefit in advanced gastric or GEJ adenocarcinoma progressing after first-line treatment, and the study findings validate VEGFR2 signaling as an important target in advanced gastric cancer.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 12(12)
Issue
The Journal of Community and Supportive Oncology - 12(12)
Page Number
428-430
Page Number
428-430
Article Type
Display Headline
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
Display Headline
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
Legacy Keywords
gastric cancer, ramucirumab, anti-VEGF, bevacizumab, aflibercept
Legacy Keywords
gastric cancer, ramucirumab, anti-VEGF, bevacizumab, aflibercept
Sections
Citation Override
JCSO 2014;12:428-430
Disallow All Ads
Alternative CME
Article PDF Media
Document